Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Since patients with (borderline) resectable pancreatic cancer have a limited life expectancy, it is important to improve treatment strategies. Therefore, the objective of this study is to investigate whether neoadjuvant triple treatment with chemotherapy (mFOLFIRINOX), immunotherapy (pembrolizumab and stereotactic radiotherapy, followed by adjuvant surgery and chemotherapy and immunotherapy, improves survival in patients with (borderline) resectabel pancreatic cancer.

Trial Details

NCT ID

NCT06384560

Phase

PHASE1 / PHASE2

Sponsor

Amsterdam UMC, location VUmc

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Pembrolizumab
Folfirinox
SABR

Locations (sample)

Amsterdam, Netherlands|52.37403,4.88969
Maastricht, Netherlands|50.84833,5.68889
Nieuwegein, Netherlands|52.02917,5.08056
Rotterdam, Netherlands|51.9225,4.47917

Key Eligibility Criteria

Histologically or cytologically confirmed adenocarcinoma of the pancreas (WHO VI or VII)
Male or female participants who are at least 18 years of age on the day of signing informed consent
Primary resectable or borderline resectable disease (DPCG criteria)
ECOG performance status 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →